Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2008 Results

orm 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


(A Development Stage Enterprise)


Three Months Ended Nine Months Ended

September 30, September 30, September 30, September 30,

2008 2007 2008 2007

Revenues from

services $- $- $- $-

Operating expenses:

Research and

development 3,792,424 13,874,248 20,375,998 34,660,132

General and

administrative 7,400,263 9,647,646 24,814,462 23,330,570

Total operating

expenses 11,192,687 23,521,894 45,190,460 57,990,702

Loss from

operations (11,192,687) (23,521,894) (4

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
(Date:10/8/2015)... , October 8, 2015 ... Global Biologics and Biosimilars industry . ... "Global Biologics and Biosimilars Industry 2015 Deep Market ... Forecast" is a professional and depth research report ... ) , --> ...
(Date:10/8/2015)... 8, 2015  The ALS Association, in partnership with ... Challenge to revolutionize communication technology solutions for people living ... ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative ... and the spinal cord. Eventually, people with ALS lose ... often leads to total paralysis and death within two ...
(Date:10/8/2015)...  Sigma-Aldrich Corporation (NASDAQ: SIAL ) announced ... its Applied Diagnostics and Testing business segment has ... line with ten certified Snap-N-Spike ® solutions ... their stable-labeled internal standards. These new solution certified ... acid and native and deuterium-labeled analogs of cholic ...
(Date:10/8/2015)... ... 2015 , ... Cystic fibrosis (CF) is a genetic disease ... results in dysfunction of the lungs and the gastrointestinal (GI) tract. In CF ... very difficult to clear, blocks the airways and the glands, and creates an ...
Breaking Biology Technology:
... 1 ChromaDex, Inc. ("ChromaDex"),today announced that effective ... Acquisition, Inc. ("CDI"), the wholly-owned subsidiary of Cody,Resources, ... ChromaDex to be wholly owned by a company ... be better positioned to meet the ongoing needs,of ...
... Will Support Development of Bavituximab and Fully Human ... ... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage ... C virus (HCV) infection, today announced it has entered into ...
... July 1 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ... $20 million in Ibis Biosciences, Inc., an Isis,subsidiary. ... the Ibis,T5000(TM) Biosensor System, which offers a unique ... By making this,investment, Abbott retains the exclusive option ...
Cached Biology Technology:
(Date:9/26/2015)... -- Results of a TactioRPM pilot project in a ... Stanford Medicine X Conference. In a presentation titled ... Devices and Pharmacogenomics", Roger Simard , Pharmacist ... senior patients equipped with connected health devices and ... TactioRPM remote patient monitoring platform were empowered to ...
(Date:9/10/2015)... , Sept. 10, 2015 This report ... wearable technology products today, and emerging sensor types that ... risen through the peak of the wearable technology hype ... slide to disillusionment. The common feature with all of ... key enabler for their most useful functions. Sensors collect ...
(Date:9/10/2015)... 2015 Pursuant Health has collaborated with ... an interactive, image-based health risk assessment (HRA) optimized ... The unique assessment quantifies user results into an ... an individual,s biological age based on personal health ... the kiosk. Comprised of age, gender, ...
Breaking Biology News(10 mins):
... of the brain, which scavenge pathogens and damaged neurons, are ... research by Duke neuroscientists. Earlier studies by Staci Bilbo, ... laboratory rats experiencing an infection at an early age have ... their learning and memory. In a study published ...
... Lake City Physicians preparing to deliver a baby look ... whether or not to perform a C- section. But a ... shows that those heart rate patterns may not be a ... lead to unnecessary interventions and higher costs. "We,re trying ...
... a class of theoretical concepts for manipulating the climate ... caused by greenhouse gasses. But its potential effectiveness and ... could help narrow these uncertainties. A team composed of ... and Harvard,s David Keith used modeling to determine the ...
Cached Biology News:
... for 25 chips provides the chips and ... (at picogram levels) with the Experion automated ... HighSens microfluidic chips, 2 x 1,250 microliters ... HighSens stain, 20 microliters RNA ladder, 2 ...
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... StdSens analysis kit for 25 chips provides ... standard-sensitivity RNA analysis (at nanogram levels) with ... includes 25 RNA StdSens microfluidic chips, 2 ... 20 microliters RNA StdSens stain, 2 x ...
... White solid. PROTECT FROM LIGHT. PACKAGED UNDER ... pyrimidinone compound that acts as a potent ... (IC 50 = 200 nM and ... with little activity against the dehydrogenase activity ...
Biology Products: